药物开发
疾病
药品
药物试验
临床试验
医学
药物发现
功效
生物标志物
生物信息学
药理学
重症监护医学
内科学
生物
生物化学
出处
期刊:Nature Medicine
[Springer Nature]
日期:2010-09-21
卷期号:16 (11): 1218-1222
被引量:123
摘要
Biomarkers may be of great value in Alzheimer's disease drug development to select the most optimal drug candidates for large and expensive phase 3 clinical trials. Biomarkers will also be important to provide evidence that a drug affects the underlying pathophysiology of the disease, which, together with a beneficial effect on the clinical course, will be essential for labeling the drug as having a disease-modifying effect.
科研通智能强力驱动
Strongly Powered by AbleSci AI